Search
Hydroxyproline
go.drugbank.com/drugs/DB08847ApprovedHydroxyproline is a neutral heterocyclic protein amino acid. It is found in collagen and as such it is common in many gelatin products. … Hydroxyproline is mostly used as a diagnostic marker of bone turnover and liver fibrosis.
Mixtures: Ouhi Cell Power No 1 Essence, Ouhi Cell Power No 1 EyeSynonyms: trans-4-Hydroxy-L-proline, trans-L-HydroxyprolineDPDPE
go.drugbank.com/drugs/DB08861ExperimentalA heterodetic cyclic peptide that is a cyclic enkephalin analogue, having D-penicillaminyl residues located at positions 2 and 5, which form the heterocycle via a disulfide bond.
Synonyms: L-tyrosyl-3-mercapto-D-valylglycyl-L-phenylalanyl-3-mercapto-D-valine, cyclic (2-5)-disulfide, (D-Pen2,D-Pen5)-EnkephalinCholecystokinin
go.drugbank.com/drugs/DB08862ApprovedInvestigationalWithdrawnCholecystokinin ( also known as _CCK or CCK-PZ_) is a peptide hormone of the gastrointestinal system which is responsible for stimulating the digestion of fat and protein. … Recent studies have suggested that cholecystokinin also plays a major role in inducing drug tolerance to opioids such as morphine and heroin, and is partially implicated in experiences of pain hypersensitivity
Teriflunomide
go.drugbank.com/drugs/DB08880ApprovedInvestigationalIt is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. … Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis.
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme InducersSynonyms: (Z)-2-cyano-alpha,alpha,alpha-trifluoro-3-hydroxy-p-crotonotoluidideLinagliptin
go.drugbank.com/drugs/DB08882ApprovedInvestigationalLinagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes [L9557]. … Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding[A37050
Mixtures: GLYXAMBI® 25 MG/ 5 MG, GLYXAMBI® 10 MG/ 5 MGCategories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesAflibercept
go.drugbank.com/drugs/DB08885ApprovedInvestigationalgamma 1 (IgG1). … [A261130] Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Daltons (kDa).
Products: EYLIA® SOLUCIÓN PARA INYECCIÓN INTRAVÍTREA, ZALTRAP 100MG/4ML INFUZYONLUK KONSANTRE COZELTI İÇEREN FLAKON, 3 ADETIcosapent ethyl
go.drugbank.com/drugs/DB08887ApprovedInvestigationalNutraceuticalIcosapent ethyl or ethyl eicosapentaenoic acid is a synthetic derivative of the omega-3 fatty acid eicosapentaenoic acid (EPA). … It is used as an adjunct therapy for severe hypertriglyceridemia (TG levels > 500 mg/dL) and to reduce the risk of cardiovascular events in certain patients with elevated triglycerides.
Categories: Fatty Acids, Omega-3Synonyms: E-EPA, (all-Z)-5,8,11,14,17-Eicosapentaenoic acid ethyl esterArbaclofen Placarbil
go.drugbank.com/drugs/DB08892InvestigationalArbaclofen Placerbil is a prodrug of Arbaclofen, which is a selective gamma-amino-butyric acid type B receptor agonist and the R-enantiomer of baclofen. … It was discovered, and has been patented by XenoPort as a new chemical entity with an improved pharmacokinetic profile compared to baclofen, which allows for sustained release properties.
Categories: GABA-B Receptor AgonistsEnzalutamide
go.drugbank.com/drugs/DB08899ApprovedInvestigational[A252667,A252642] Due to a favorable pharmacological profile, a phase 1 study of enzalutamide was initiated in July 2007. … [L40639] It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesProducts: XTANDI ® 40 MG, XTANDI® 40 MGRaxibacumab
go.drugbank.com/drugs/DB08902ApprovedInvestigationalRaxibacumab is a human IgG1λ monoclonal antibody that binds the protective antigen (PA) component of B. anthracis toxin. Raxibacumab has a molecular weight of approximately 146 kilodaltons. … Raxibacumab is produced by recombinant DNA technology in a murine cell expression system. FDA approved on December 14, 2012.